CLINICAL TRIAL article
Front. Pharmacol.
Sec. Ethnopharmacology
This article is part of the Research TopicHerbal Medicine for the Treatment of Chronic Metabolic Diseases, Volume IIView all 54 articles
Efficacy and Safety of Yingxin Pill for Stable Angina Pectoris with Heart Blood Stasis Obstruction Syndrome: A Randomized, Single-Blind, Positive-Controlled Trial
Provisionally accepted
- 1Department of Cardiology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China
- 2Hohhot Maternal and Child Health Hospital, Hohhot, China
- 3Chinese PLA General Hospital, Beijing, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: To evaluate the clinical efficacy and safety of Yingxin Pill (YXP) in patients with stable angina pectoris (SAP) and heart blood stasis obstruction syndrome. Methods: Sixty patients were randomly assigned to either the experimental group (YXP plus conventional Western medicine) or the control group (Shexiang Baoxin Pill [SBP] plus conventional Western medicine), with 30 patients in each group. Treatment lasted for 4 weeks. Outcomes included the Seattle Angina Questionnaire (SAQ), a Traditional Chinese Medicine (TCM) efficacy scale, blood lipid profiles, and inflammatory markers. The effective rate and incidence of adverse events were also compared. Results: After treatment, both groups showed significant improvements in SAQ scores, TCM efficacy scale scores, lipid profiles, and inflammatory markers compared to baseline (P<0.05). There were no significant differences between the two groups in these outcomes, nor in the total effective rate or incidence of adverse events (P>0.05). Conclusions: The addition of YXP to conventional therapy can improve symptoms, reduce blood lipid and inflammation levels, and is safe for patients with SAP and heart blood stasis obstruction syndrome.
Keywords: Blood lipid, Inflammatory markers, positive-controlled clinical trial, Stable angina pectoris, Traditional Chinese Medicine, yingxin pill
Received: 23 Oct 2025; Accepted: 28 Jan 2026.
Copyright: © 2026 NIU, Lai, Wang, Wu, Zhang, Wei, Sun, Shi and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Lijing Zhang
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.